Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo.

Details

Serval ID
serval:BIB_260FD4BEF65D
Type
Article: article from journal or magazin.
Collection
Publications
Title
Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo.
Journal
Journal of Immunology
Author(s)
Brunner C., Seiderer J., Schlamp A., Bidlingmaier M., Eigler A., Haimerl W., Lehr H.A., Krieg A.M., Hartmann G., Endres S.
ISSN
0022-1767 (Print)
ISSN-L
0022-1767
Publication state
Published
Issued date
2000
Volume
165
Number
11
Pages
6278-6286
Language
english
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Abstract
Dendritic cells (DC) manipulated ex vivo can induce tumor immunity in experimental murine tumor models. To improve DC-based tumor vaccination, we studied whether DC maturation affects the T cell-activating potential in vitro and the induction of tumor immunity in vivo. Maturation of murine bone marrow-derived DC was induced by GM-CSF plus IL-4 alone or by further addition of TNF-alpha or a cytidine-phosphate-guanosine (CpG)-containing oligonucleotide (ODN-1826), which mimics the immunostimulatory effect of bacterial DNA. Flow cytometric analysis of costimulatory molecules and MHC class II showed that DC maturation was stimulated most by ODN-1826, whereas TNF-alpha had an intermediate effect. The extent of maturation correlated with the secretion of IL-12 and the induction of alloreactive T cell proliferation. In BALB/c mice, s.c. injection of colon carcinoma cells resulted in rapidly growing tumors. In this model, CpG-ODN-stimulated DC cocultured with irradiated tumor cells also induced prophylactic protection most effectively and were therapeutically effective when administered 3 days after tumor challenge. Thus, CpG-ODN-enhanced DC maturation may represent an efficient means to improve clinical tumor vaccination.
Keywords
Adjuvants, Immunologic/pharmacology, Adjuvants, Immunologic/therapeutic use, Animals, Antineoplastic Agents/immunology, Antineoplastic Agents/therapeutic use, Cell Communication/immunology, Cell Differentiation/immunology, Cells, Cultured, Coculture Techniques, Colonic Neoplasms/immunology, Colonic Neoplasms/pathology, CpG Islands/immunology, Dendritic Cells/cytology, Dendritic Cells/immunology, Female, Growth Inhibitors/immunology, Growth Inhibitors/therapeutic use, Immunotherapy, Adoptive/methods, Interleukin-12/biosynthesis, Interleukin-4/pharmacology, Lymphocyte Activation/immunology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasm Transplantation, Oligodeoxyribonucleotides/immunology, Oligodeoxyribonucleotides/therapeutic use, T-Lymphocytes/immunology, Tumor Cells, Cultured/immunology, Tumor Cells, Cultured/transplantation, Tumor Necrosis Factor-alpha/immunology
Pubmed
Create date
26/11/2011 14:06
Last modification date
20/08/2019 14:04
Usage data